கட்டி திசு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article EAST HANOVER, N.J., June 3, 2021 /PRNewswire/ Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera ® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus 30 mg octreotide LAR to 60 mg of octreotide LAR in patients with midgut neuroendocrine tumors. The previously reported primary analysis of the trial demonstrated a statistically significant improvement in progression free survival (PFS) (HR: 0.18 , p 0.0001) 3. In the final analysis of overall survival, a secondary objective of the trial, treatment with Lutathera resulted in a clinically relevant prolongation in median overall survival of 11.7 months [48.0 months (95%CI: 37.4-55.2) compared to the control arm (36.3 months (95%CI: 25.9-51.7)]

United statesIsabella zinckSamir shahJulie masowThomas hungerbuehlerSloan simpsonRachel levinePrnewswire novartisNuclear medicine through innovationVirtual scientific programNovartis companyElsevier incNovartis external communicationsExchange commissionNational cancer institute surveillanceNational research council